Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

17 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-28

Study Completion Date

2021-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is assessing the impact of timing of PD assessments on measures of platelet reactivity in patients undergoing PCI treated with cangrelor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor

NCT00102674

Healthy

COMPLETED PHASE1

Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention

NCT06089577

Coronary Artery Disease

RECRUITING PHASE4

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

NCT03247738

ST Segment Elevation Myocardial Infarction Percutaneous Coronary Intervention

COMPLETED PHASE4

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

NCT00385138

Atherosclerosis Acute Coronary Syndrome (ACS)

TERMINATED PHASE3

Cangrelor to Clopidogrel or Prasugrel Transition Study

NCT01979445

Coronary Artery Disease (CAD)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cangrelor is characterized by reversible binding to the P2Y12 receptor and is promptly inactivated through dephosphorylation by ectonucleotidase leading to its very short plasma half-life. Consequently the timing at which PD assessments are performed after blood sample collection may impact measures of platelet reactivity in patients treated with cangrelor. We therefore hypothesize that measures of platelet inhibitory effects observed in cangrelor treated patients will reduce with time following blood sampling.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cangrelor Group

This is the study cohort that the blood sample will be obtained from. There are no interventions

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years old
* CAD patients (stable CAD, NSTE-ACS, or STEMI) undergoing PCI and treated with cangrelor per standard of care.
* Treated with aspirin prior to the PCI procedure per standard of care

Exclusion Criteria

* Treatment with an oral P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) within past 10 days
* Treatment with oral anticoagulation (vitamin K antagonist, dabigatran, apixaban, rivaroxiban) within past 3 days
* Treatment with a glycoprotein IIb/IIIa inhibitor during PCI
* Fibrinolytics within 48 hours
* Known hemoglobin\<10 gm/dL
* Known platelet count \<80x106/mL
* Active bleeding or hemodynamic instability
* Known end stage renal disease on hemodialysis
* Known severe hepatic dysfunction

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No